Optimizing Treatment Outcomes in Advanced NSCLC with Concurrent Biomarker Testing - Episode 5

Biomarker Testing in Early-Stage NSCLC

,

Medical experts recommend that EGFR, ALK, and PD-L1 testing be performed as reflex tests for patients with early-stage non-small cell lung cancer to inform personalized treatment strategies.

  1. What do available data show regarding the impact of concurrent testing on 1L therapy in advanced NSCLC? (Brief high-level overview only)
    1. Raez, et al. Clin Lung Cancer, 2023
    2. ACCELERATE – Garcia-Pardo, et al. JAMA Netw Open, 2023
  • Please comment on turnaround time for results, time to 1L treatment.